Irritable Bowel Syndrome – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
MARKET OUTLOOK
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea predominant subtype. Limited treatment options are available for IBS, and only a few drugs have secured FDA approval for IBS-D. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), an antibiotic (Salix Pharmaceuticals’ Xifaxan), and an opioid delta receptor antagonist (AbbVie’s Viberzi).
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
- How have Viberzi and Xifaxan been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: AbbVie, Salix, Sebela Pharmaceuticals.
Key drugs: Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate.
Table of contents
- Irritable Bowel Syndrome - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - IBS-Diarrhea (US)
- Treatment Algorithms Claims Data Analysis Diarrhea Predominant Irritable Bowel Syndrome US January 2022
- Treatment Algorithms Claims Data Analysis Diarrhea Predominant Irritable Bowel Syndrome US 2022 Dashboard
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.